JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Innoviva Inc

Closed

SectorHealthcare

17.55 -1.13

Overview

Share price change

24h

Current

Min

17.38

Max

17.8

Key metrics

By Trading Economics

Income

110M

64M

Sales

12M

100M

P/E

Sector Avg

31.088

37.003

Profit margin

63.508

Employees

127

EBITDA

111M

84M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+114.81% upside

Dividends

By Dow Jones

Next Earnings

4 lis 2025

Market Stats

By TradingEconomics

Market Cap

-50M

1.1B

Previous open

18.68

Previous close

17.55

News Sentiment

By Acuity

42%

58%

157 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Innoviva Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 paź 2025, 23:28 UTC

Hot Stocks

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 paź 2025, 23:07 UTC

Earnings

Prudential PLC 3Q New Business Profit Up 13%

30 paź 2025, 00:00 UTC

Earnings

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 paź 2025, 00:00 UTC

Earnings

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 paź 2025, 00:00 UTC

Earnings

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 paź 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 paź 2025, 23:40 UTC

Earnings

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 paź 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 paź 2025, 23:25 UTC

Earnings

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 paź 2025, 22:51 UTC

Earnings

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 paź 2025, 22:45 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 paź 2025, 22:41 UTC

Earnings

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 paź 2025, 22:41 UTC

Earnings

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 paź 2025, 22:09 UTC

Earnings

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 paź 2025, 22:08 UTC

Market Talk
Earnings

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 paź 2025, 21:58 UTC

Earnings

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 paź 2025, 21:58 UTC

Earnings

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 paź 2025, 21:57 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 paź 2025, 21:54 UTC

Earnings

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 paź 2025, 21:46 UTC

Earnings

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 paź 2025, 21:43 UTC

Earnings

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 paź 2025, 21:43 UTC

Earnings

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 paź 2025, 21:42 UTC

Earnings

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 paź 2025, 21:42 UTC

Earnings

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 paź 2025, 21:41 UTC

Earnings

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 paź 2025, 21:41 UTC

Earnings

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 paź 2025, 21:41 UTC

Earnings

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 paź 2025, 21:41 UTC

Earnings

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 paź 2025, 21:40 UTC

Earnings

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 paź 2025, 21:39 UTC

Earnings

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

114.81% upside

12 Months Forecast

Average 38 USD  114.81%

High 55 USD

Low 17 USD

Based on 4 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

3

Buy

0

Hold

1

Sell

Technical Score

By Trading Central

18.57 / 18.75Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

157 / 373 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat